본문 바로가기
KERD
논문KCI 등재

Usefulness of BK virus-specific interferon-γ enzyme-linked immunospot assay for predicting the outcome of BK virus infection in kidney transplant recipients

Hyeyoung Lee|Ki Hyun Park|Byung Ha Chung|Eun Jeong Ko|Chul Woo Yang|Hyunjoo Bae|Do Hyun Na|Ji-Yeun Chang|Ji Won Min|Eun-Jee Oh
대한내과학회 (The Korean Association Of Internal Medicine)|2021.01|The Korean Journal of Internal Medicine|제36권 제1호|pp. 164-174|DOI https://doi.org/10.3904/kjim.2019.339

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

Kidney transplantationBK virusEnzyme-linked immunospot assayViremiaBK polyomavirus-associated nephropathy
주제분류내과학

초록

Background/Aims: To investigate if BK virus (BKV)-specific T cell immunity measured by an interferon-γ enzyme-linked immunospot (ELISPOT) assay can predict the outcome of BK virus infection in kidney transplant recipients (KTRs). Methods: We included 68 KTRs with different viremia status (no viremia [n = 17], BK viremia [n = 27], and cleared viremia [n = 24]) and 44 healthy controls (HCs). The BK viremia group was divided into controller (< 3 months) and noncontroller (> 3 months) according to sustained duration of BKV infection. We compared BKV-ELISPOT results against five BKV peptides (large tumor antigen [LT], St, VP1-3). Results: BKV-ELISPOT results were higher in three KTRs groups with different BKV infection status than the HCs group (p < 0.05). In KTR groups, they were higher in cleared viremia group than no viremia or BK viremia group. Within the BK viremia group, controller group had higher LT-ELISPOT results compared to noncontroller group (p = 0.032). Also, KTRs without BK virus-associated nephropathy (BKVN) had higher LT, St, VP1, and VP2-ELISPOT results than those with BKVN (p < 0.05). Conclusions: BKV-ELISPOT assay may be effective in predicting clinical outcomes of BKV infection in terms of clearance of BK virus and development of BKVN.

Abstract

Background/Aims: To investigate if BK virus (BKV)-specific T cell immunity measured by an interferon-γ enzyme-linked immunospot (ELISPOT) assay can predict the outcome of BK virus infection in kidney transplant recipients (KTRs). Methods: We included 68 KTRs with different viremia status (no viremia [n = 17], BK viremia [n = 27], and cleared viremia [n = 24]) and 44 healthy controls (HCs). The BK viremia group was divided into controller (< 3 months) and noncontroller (> 3 months) according to sustained duration of BKV infection. We compared BKV-ELISPOT results against five BKV peptides (large tumor antigen [LT], St, VP1-3). Results: BKV-ELISPOT results were higher in three KTRs groups with different BKV infection status than the HCs group (p < 0.05). In KTR groups, they were higher in cleared viremia group than no viremia or BK viremia group. Within the BK viremia group, controller group had higher LT-ELISPOT results compared to noncontroller group (p = 0.032). Also, KTRs without BK virus-associated nephropathy (BKVN) had higher LT, St, VP1, and VP2-ELISPOT results than those with BKVN (p < 0.05). Conclusions: BKV-ELISPOT assay may be effective in predicting clinical outcomes of BKV infection in terms of clearance of BK virus and development of BKVN.

참고문헌 (41)

  1. Ramos E, "BK virus nephropathy diagnosis and treatment : experience at the University of Maryland Renal Transplant Program", Clin Transpl, pp.143~153 (2002)
  2. Brennan DC, "Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction", Am J Transplant, 5, pp.582~594 (2005)
  3. 박우영, "Long-term prognosis of BK virus-associated nephropathy in kidney transplant recipients", Kidney Research and Clinical Practice, 37(2), pp.167~173 (2018), 대한신장학회
  4. Hirsch HH, "Polyomavirus-associated nephropathy in renal transplantation : interdisciplinary analyses and recommendations", Transplantation, 79, pp.1277~1286 (2005)
  5. Yi SG, "BK virus as a mediator of graft dysfunction following kidney transplantation", Curr Opin Organ Transplant, 22, pp.320~327 (2017)
  6. Vasudev B, "BK virus nephritis : risk factors, timing, and outcome in renal transplant recipients", Kidney Int, 68, pp.1834~1839 (2005)
  7. Yon Su Kim, "Open the black box; is urine valuable for screening BK virus-associated nephropathy?", Kidney Research and Clinical Practice, 35(3), pp.131~132 (2016), 대한신장학회
  8. W. James Chon, "High-level viruria as a screening tool for BK virus nephropathy in renal transplant recipients", Kidney Research and Clinical Practice, 35(3), pp.176~181 (2016), 대한신장학회
  9. Sawinski D, "Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies", J Am Soc Nephrol, 26, pp.966~975 (2015)
  10. Babel N, "Sustained BK viruria as an early marker for the development of BKV-associated nephropathy : analysis of 4128 urine and serum samples", Transplantation, 88, pp.89~95 (2009)
  11. Bonvoisin C, "Polyomavirus in renal transplantation : a hot problem", Transplantation, 85(7 Suppl), pp.S42~S48 (2008)
  12. Nickel P, "High levels of CMV-IE1-specific memory T cells are associated with less alloimmunity and improved renal allograft function", Transpl Immunol, 20, pp.238~242 (2009)
  13. 이새미, "Clinical Usefulness of Monitoring Cytomegalovirus-Specific Immunity by Quantiferon-CMV in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients", Annals of Laboratory Medicine, 37(3), pp.277~281 (2017), 대한진단검사의학회
  14. Lee H, "Cytomegalovirus(CMV)immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients", PLoS One, 12, pp.e0189488~ (2017)
  15. Schachtner T, "BK virus-specific immunity kinetics : a predictor of recovery from polyomavirus BK-associated nephropathy", Am J Transplant, 11, pp.2443~2452 (2011)
  16. Binggeli S, "Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients", Am J Transplant, 7, pp.1131~1139 (2007)
  17. Egli A, "Inhibition of polyomavirus BK-specific T-cell responses by immunosuppressive drugs", Transplantation, 88, pp.1161~1168 (2009)
  18. Leboeuf C, "BK polyomavirus-specific 9mer CD8 T cell responses correlate with clearance of BK viremia in kidney transplant recipients : first report from the Swiss transplant cohort study", Am J Transplant, 17, pp.2591~2600 (2017)
  19. Calarota SA, "Approaches for monitoring of non virus-specific and virus-specific T-cell response in solid organ transplantation and their clinical applications", J Clin Virol, 70, pp.109~119 (2015)
  20. Chakera A, "Antigen-specific T cell responses to BK polyomavirus antigens identify functional anti-viral immunity and may help to guide immunosuppression following renal transplantation", Clin Exp Immunol, 165, pp.401~409 (2011)
  21. Schachtner T, "The loss of BKV-specific immunity from pretransplantation to posttransplantation identifies kidney transplant recipients at increased risk of BKV replication", Am J Transplant, 15, pp.2159~2169 (2015)
  22. Schachtner T, "Inflammatory activation and recovering BKV-specific immunity correlate with self-limited BKV replication after renal transplantation", Transpl Int, 27, pp.290~301 (2014)
  23. Cioni M, "Characterization of immunodominant BK polyomavirus 9mer epitope T cell responses", Am J Transplant, 16, pp.1193~1206 (2016)
  24. Chung BH, "Clinical usefulness of BK virus plasma quantitative PCR to prevent BK virus associated nephropathy", Transpl Int, 25, pp.687~695 (2012)
  25. Costa C, "Monitoring of BK virus replication in the first year following renal transplantation", Nephrol Dial Transplant, 23, pp.3333~3336 (2008)
  26. Schaenman JM, "Increased frequency of BK virus-specific polyfunctional CD8+ T cells predict successful control of BK viremia after kidney transplantation", Transplantation, 101, pp.1479~1487 (2017)
  27. Hirsch HH, "BK polyomavirus in solid organ transplantation", Am J Transplant, 13(Suppl 4), pp.179~188 (2013)
  28. Polz D, "BK-virus(BKV) : structure, epidemiology and pathogenesis", J Pre-Clin Clin Res, 7, pp.90~92 (2013)
  29. Bechert CJ, "Monitoring of BK viral load in renal allograft recipients by real-time PCR assays", Am J Clin Pathol, 133, pp.242~250 (2010)
  30. Hirsch HH, "Polyomavirus BK nephropathy : a(re-)emerging complication in renal transplantation", Am J Transplant, 2, pp.25~30 (2002)
  31. Comoli P, "Polyomavirus-associated nephropathy : update on BK virus-specific immunity", Transpl Infect Dis, 8, pp.86~94 (2006)
  32. El-Husseini A, "Impact of human leukocyte antigen and calculated panel reactive antibody on BK viremia in kidney transplant recipients : a single-center experience and literature review", Transpl Infect Dis, 21, pp.e13071~ (2019)
  33. Awadalla Y, "HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients", Am J Transplant, 4, pp.1691~1696 (2004)
  34. Hassig A, "Association of BK viremia with human leukocyte antigen mismatches and acute rejection, but not with type of calcineurin inhibitor", Transpl Infect Dis, 16, pp.44~54 (2014)
  35. Kim H, "Clinical courses of renal transplant recipients with high BK viremia", Transplant Proc, 45, pp.2975~2979 (2013)
  36. Randhawa P, "Correlates of quantitative measurement of BK polyomavirus(BKV)DNA with clinical course of BKV infection in renal transplant patients", J Clin Microbiol, 42, pp.1176~1180 (2004)
  37. Hasegawa M, "Association of DNA amplification with progress of BK polyomavirus infection and nephropathy in renal transplant recipients", Transplant Pro, 46, pp.556~559 (2014)
  38. Elfadawy N, "Transient versus persistent BK viremia and long-term outcomes after kidney and kidney-pancreas transplantation", Clin J Am Soc Nephrol, 9, pp.553~561 (2014)
  39. Kidney Disease : Improving Global Outcomes(KDIGO)Transplant Work Group, "KDIGO clinical practice guideline for the care of kidney transplant recipients", Am J Transplant, 9(Suppl 3), pp.S1~S155 (2009)
  40. Abend JR, "Correlation of BK virus neutralizing serostatus with the incidence of BK viremia in kidney transplant recipients", Transplantation, 101, pp.1495~1505 (2017)
  41. Solis M, "Neutralizing antibody-mediated response and risk of BK virus-associated nephropathy", J Am Soc Nephrol, 29, pp.326~334 (2018)

이 간행물의 다른 논문 (60건)

Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world studyYoun Jae Lee, Eun Sun Jang, Young Seok Kim, In Hee Kim, Kyung-Ah Kim, Woo Jin Chung, Byung Seok Lee, Sook-Hyang Jeongpp. 1-8Clinical implication and risk factor of pneumonia development in mild coronavirus disease 2019 patients이현우, 정희순, Jung Kyu Lee, Deog Kyeom Kim, Eun Young Heo, Seo-Young Yoon, Tae Yeon Parkpp. 1-10Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel diseaseJaewoo Park, Nayoung Kim, Dong Ho Lee, Young Soo Park, Hye Ran Yang, Joo Sung Kim, Hyuk Yoon, Cheol Min Shin, Seung Wook Hongpp. 9-17Dynamics of viral load and anti-SARS-CoV-2 antibodies in patients with positive RT-PCR results after recovery from COVID-19Jongtak Jung, Sin Young Ham, Sang-Min Oh, Chang Kyung Kang, Yu Min Kang, Hyunju Lee, Ji Young Park, 송경호, Jeong Su Park, Hong Bin Kim, Kyoung Un Park, Eu Suk Kim, Hyeonju Jeong, 김동민, Ji-Yeon Kimpp. 11-14Acute pancreatitis and diabetes mellitus: a reviewWalter G. Park, Allyson Richardsonpp. 15-24
원문 보기